**BRAF Oncogenic Mutations Correlate with Progression rather than Initiation of Human Melanoma**

Jianli Dong, Robert G. Phelps, Rui Qiao, Shen Yao, Outhiriaradjou Benard, Zeev Ronai, and Stuart A. Aaronson

Department of Pathology [J. D., R. G. P.], Ruttenberg Cancer Center [J. D., R. Q., S. Y., O. B., Z. R., S. A. A.], and Department of Dermatology [R. G. P.], Mount Sinai School of Medicine, New York, New York 10029

**Abstract**

**BRAF** oncogenic mutations have been identified in significant numbers of melanocytic lesions. To correlate **BRAF** mutation and melanoma progression, we screened **BRAF** mutations in 65 melanocytic lesions, including nevi, radial growth phase (RGP), vertical growth phase (VGP) melanomas, and melanoma metastases, as well as 25 melanoma cell lines. PCR and direct sequencing were used to analyze DNA samples extracted from laser capture microdissected tissues. A similar high frequency (62–72%) of **BRAF** oncogenic mutations was identified in melanocytic nevi, VGP, metastatic melanomas, and melanoma cell lines [H. Davies et al., Nature (Lond.), 417: 949–954, 2002; P. M. Pollock et al., Nat. Genet., 33: 19–20, 2002; and M. S. Brose et al., Cancer Res., 62: 6997–7000, 2002]. In striking contrast, we found **BRAF** lesions in only 10% of the earliest stage or RGP melanomas. These findings imply that **BRAF** mutations cannot be involved in the initiation of the great majority of melanomas but instead reflect a progression event with important prognostic implications in the transition from the great majority of RGP melanomas to VGP and/or metastatic melanoma.

**Introduction**

**BRAF** encodes a serine/threonine kinase that acts in the MAPK pathway to transduce regulatory signals from RAS through MEK (MAPK kinase) to MAPK. Recently, mutations in **BRAF** have been reported at high frequency ranging from 59 to 80% in melanoma samples, including tumor cell lines, short-term cultures, and tumor tissues (1). A T1796A transversion in exon 15, resulting in a V599E missense mutation, accounts for >90% of mutations detected in melanoma samples (1). The V599E mutation has been shown to increase **BRAF** kinase activity and to cause it to acquire transforming activity in the NIH3T3 transfection assay (1). Pollock et al. (2) recently reported that the incidence of **BRAF**-activating mutations in nevi, including congenital, acquired, compound, and dysplastic, ranged from 70 to 88%, consistent with the hypothesis that this pathway to transduce regulatory signals from RAS through MEK might be involved in the progression of human melanoma.

**Materials and Methods**

**Tumor Samples and Melanoma Cell Lines.** Formalin-fixed and paraffin-embedded tissues, including 24 melanocytic nevi, 20 RGPs, 8 VGPs, and 13 melanoma metastases, were obtained from the Pathology Department of Mount Sinai School of Medicine. The diagnosis of a melanocytic nevus was based on a well-established constellation of criteria. The epidermis and dermis contained a symmetrical ordered, sharply demarcated melanocytic proliferation. The melanocytes were present as small clusters in the epidermis or dermis, exhibited minimal cytological atypia, and did not show significant mitotic figures. The melanocytes also showed changes in response to the microenvironment in that their nuclei became smaller and more neuritid with descent deeper in the dermis (maturation), and there was more pigment superficially. The diagnosis of RGP and VGP melanoma was made according to well-established criteria. RGP melanomas consisted of cases in which the melanoma cells were confined either to the epidermis only (malignant melanoma in situ RGP) or confined to the superficial papillary dermis (malignant melanoma microinvasive RGP). By definition, if the cells entered the dermis, the nests in the dermis could not be larger than the largest intraepidermal cluster and could not exhibit mitoses. The VGP melanoma was defined by the presence of an invasive dermal component in which the cells in the dermis were larger than the largest intraepidermal cluster of melanocytes or showed significant mitotic activity. Other features that were helpful in establishing the VGP diagnosis included that the cells in the dermis were more morphologically atypical, irregular shaped, or showed foci of necrosis, i.e., cytologic evidence that a new, potentially tumorigenic clone of melanocytes was forming (5).

In addition, 25 human melanoma cell lines obtained from American Type Culture Collection, Dr. Meenhard Herylin (Wistar Institute, Philadelphia, PA), or established by us were included in the study.

**LCM and DNA Extraction.** Formalin-fixed and paraffin-embedded tissue sections were histologically evaluated for the presence of melanocytic lesions, including melanocytic nevi, RGP, VGP, and metastatic melanomas. Pure populations of cells were carefully microdissected using a PixCell II Laser Capture Microdissection System (Arcturus, Mountain View, CA) according to the manufacturer’s instructions. A total of >200 cells was collected in each case from serial tissue sections. Collected cells were transferred to an Eppendorf tube and resuspended in 20–50 μl of lysis buffer containing 10 mM Tris, 0.5% Tween 20 (pH 8.3), and 5 μl of proteinase K (20 mg/ml). Samples were incubated 1–2 days at 55°C followed by boiling for 10 min to inactivate proteinase K. Microdissection and DNA extraction were repeated as required. The Puregene Cell and Tissue Kit was used to extract DNA from cultured cells according to the manufacturer’s protocol (Genta, Minneapolis, MN).

**PCR and Direct Sequencing.** PCR was performed using forward and reverse primer sequences as described previously (1). PCR amplification was carried out with genomic DNA in a volume of 50 μl containing 20 mM Tris–HCl (pH 8.4), 50 mM KCl, 2.5 mM MgCl₂, 200 μM deoxynucleotide triphosphate, 50 pmol of forward and reverse primers, 20 μM/ml BSA, 5 units of TaqDNA polymerase (Invitrogen, Carlsbad, CA), and 3–10 μl of crude DNA extract of microdissected cells or 100 μg of purified DNA from cultured cells. PCR products were purified using QIAquick PCR Purification Kit (Qiagen, Valencia, CA). The purified PCR products were directly sequenced on both strands using a Prism Model 3700 Capillary Array Sequencer and Big Dye Terminator Chemistry (Applied Biosystems, Foster City, CA). Sequence analysis was based on **BRAF** and **NRAS** cDNA sequences (GenBank access nos. NM_004333 for **BRAF**, and NM_002524 for **NRAS**).
Results and Discussion

We screened BRAF exon 15 sequences in LCM RGP melanomas (Fig. 1A) and compared results with a similar analysis of VGP melanomas, which commonly arise within the RGP and exhibit a high potential for metastatic spread, as well as metastatic melanomas and melanoma cell lines. The frequencies of BRAF mutations in nevi, VGP, and metastatic melanomas were high, ranging from 62 to 71% (Table 1). However, RGP melanomas exhibited BRAF mutations in only 2 of 20 (10%) analyzed. NRAS-activating lesions are also found in melanomas (1, 2, 5, 6), but do not generally overlap with BRAF mutations in the same lesion (1, 2, 5). Thus, we also sequenced NRAS exons 2 and 3 surrounding codons 12, 13, and 61, the hot spots for oncogenic-activating mutations (1, 2, 5, 6), in all BRAF wild-type samples. NRAS mutations were not detected in RGP samples but were found in other lesions and increased the combined BRAF and NRAS mutation frequencies to 75% in VGP, 69% in metastasis, and 84% in melanoma cell lines (Table 1). The great disparity in the frequency of BRAF mutations in nevi and RGP melanomas was highly statistically significant (Fisher’s exact test, P < 0.00006). The difference between the frequency of BRAF mutations in VGP (63%) or metastatic melanoma (62%) and RGP melanoma was also statistically significant whether compared separately (P < 0.01 or P < 0.005) or pooled (P < 0.001).

As has been recently reported (1, 2, 5), we observed (Fig. 1B) that the great majority of BRAF mutations identified were T1796A transversions, which change the wild-type codon GTG (valine) to GAG (glutamate) at position 599 (V599E). In several tested cases, these mutations were not present in normal cells from the same individuals, indicating that they were somatically acquired. One VGP melanoma and one metastasis (Fig. 1B) showed the same two-nucleotide substitution, which changes the wild-type codon GTG (valine) to AAG (lysine), at position 599 (V599K). To examine the transforming ability of the V599E and V599K BRAF mutants, pCEV29 expression constructs for T1796A/BRAF, GT1795–1796AA/BRAF, and wild-type/BRAF cDNAs were transfected into NIH3T3 cells. Comparable transforming activities were observed for the two mutants (~5000 foci/μg DNA compared with <1.0 focus/μg DNA for wild-type BRAF). Mass cultures of marker selected NIH3T3-transformed cells with either T1796A/BRAF or GT1795–1796AA/BRAF produced rapidly growing tumors in SCID mice (data not shown). Mutations in BRAF V599 codon have been shown to create an acidic or basic amino acid substitution, V599E, D, K, or R (1, 2, 5), and our results show that either type of substitution can comparably activate BRAF. We also identified loss of heterozygosity in 3 metastatic melanomas, including one with a V599K mutation (Fig. 1B), and in 16 of 18 (89%) melanoma cell lines carrying BRAF mutations (data not shown). It is possible that deletion of the wild-type allele represents an additional genetic selection in aggressive melanoma cells.

Although our present results confirm the high frequency of BRAF mutations both in nevi and later stage melanomas, our demonstration that early stage (RGP) melanomas exhibit a very low frequency of BRAF mutation argues strongly that BRAF mutation cannot be involved in the initiation of the great majority of melanomas but instead reflects a progression event. There are profound differences between RGP and VGP melanoma cells at the cellular and functional level. In RGP, neoplastic cells spread in the epidermis or invade dermis only as single cells or small clusters of nonproliferating tumor cells. In VGP, cancer cells expand in the dermis and generate tumor nodules. Unlike VGP cells, RGP melanoma cells are difficult to maintain in long-term tissue culture, have low colony-forming ability, are nontumorigenic in nude mice, and do not have the competence to metastasize (7, 8). When melanoma is diagnosed as RGP, the disease can be cured by proper surgical excision. However, tumors in VGP have acquired metastatic capability and may be resistant to current methods of therapy. Therefore, the distinction between RGP versus VGP has

---

Table 1: BRAF mutation frequencies in different stages of melanoma progression

<table>
<thead>
<tr>
<th>Sample</th>
<th>BRAF mutation frequency</th>
<th>NRAS mutations in BRAF wild-type lesions</th>
<th>Combined mutation frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melanocytic nevi (benign)</td>
<td>17/24</td>
<td>0/7</td>
<td>71%</td>
</tr>
<tr>
<td>RGP (early melanoma)</td>
<td>2/20</td>
<td>0/18</td>
<td>10%</td>
</tr>
<tr>
<td>VGP (invasive melanoma)</td>
<td>5/8</td>
<td>1/3</td>
<td>75%</td>
</tr>
<tr>
<td>Metastatic melanoma</td>
<td>8/13</td>
<td>1/5</td>
<td>69%</td>
</tr>
<tr>
<td>Melanoma cell lines</td>
<td>18/25</td>
<td>3/7</td>
<td>84%</td>
</tr>
</tbody>
</table>

---

Fig. 1. Microdissection of RGP melanoma and mutations in the BRAF gene. A, representative LCM of a RGP melanoma. Before, after microdissection, and dissected tumor cells. LCM achieved >90% tumor cell population in each case. B, mutations in the BRAF codon 599, wild-type T1796, heterozygous T1796A mutation, 2-base GT1795–1796AA substitution, and loss of heterozygosity of T1796A mutation. Formalin-fixed and paraflin-embedded tissue sections were evaluated by histopathology for the presence of melanocytic nevus, RGP, VGP, and metastasis. The sensitivity of the mutation analysis was examined using mixtures of different ratios of BRAF wild-type and mutant alleles. It was possible to detect the BRAF mutation in a 3:1 mixture of wild-type and heterozygous mutant DNA.
profound prognostic and therapeutic implications. Our present findings strongly imply that BRAF mutations most commonly represent genetic progression events in melanomas and thus may serve as biomarkers for disease progression in the important clinical distinction between RGP and VGP melanomas.

It should be noted that comparable BRAF mutation frequencies of 86, 88, 70, and 80% were reported in various nevi specimens, including congenital, intradermal, compound, and dysplastic (also termed atypical; Ref. 2), suggesting that BRAF mutations do not likely contribute to possible differences in the propensity to progress to melanoma among these nevi groups. There are a very large number of melanocytic nevi in the general population compared with the relatively low incidence of melanoma (7–9). It is known clinically that nevi very often regress over time. In tissue culture, oncogenically activated melanocytic nevi in the general population compared with the relative low incidence of melanoma (7–9). It is known clinically that nevi very often regress over time. In tissue culture, oncogenically activated RAS or RAF has been shown to induce permanent growth arrest/senescence rather than unrestricted proliferation in normal fibroblasts through a mechanism involving p53, p21Cip1, or p16 up-regulation (10–13). For example, RAF or RAF oncogenic stress mediated by extracellular signal-regulated kinase leads to increased alternative reading frame (ARF) at the level of transcription and ARF inactivates mouse double minute 2 homolog (MDM2), which targets p53 for proteosomal degradation (14, 15). Thus, such stress up-regulates p53 and its transcriptional target, p21Cip1, which is growth inhibitory to cells (16, 17). There are also reports that p21Cip1 up-regulation plays an important role in the terminal differentiation of a number of cell types (18). Whether this explains the absence of progression of the vast majority of BRAF mutation-containing nevi to melanoma awaits additional study.

Acknowledgments

We thank Jonine Bernstein for statistical analysis.

References

BRAF Oncogenic Mutations Correlate with Progression rather than Initiation of Human Melanoma

Jianli Dong, Robert G. Phelps, Rui Qiao, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/63/14/3883

Cited articles
This article cites 16 articles, 7 of which you can access for free at:
http://cancerres.aacrjournals.org/content/63/14/3883.full.html#ref-list-1

Citing articles
This article has been cited by 30 HighWire-hosted articles. Access the articles at:
/content/63/14/3883.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.